RxDoctor Payments Data

Jasmina Ouhri, PA

Medical · Sarasota, FLNPI 1194114736

Payments from drug & device makers

$2,576in general payments, 2019–2025

Across 87 payments — averaging $29.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$704
  • Kerecis Limited$381
  • Organogenesis Inc.$372
  • Astellas Pharma US Inc$305
  • Mimedx Group, Inc.$222
  • Next Science LLC$221
  • plus $371 from 8 others

What the payments were for

  • Food & beverage$2,27188%
  • Education$30512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew37$704
Kerecis Limited7$381
Organogenesis Inc.5$372
Astellas Pharma US Inc5$305
Mimedx Group, Inc.9$222
Next Science LLC11$221
Viiv Healthcare Company1$125
Convatec Inc.3$67
Hartmann USA, Inc.3$54
Hydrofera LLC2$43
KCI USA, Inc.1$24
Surgenex LLC1$23
Reprise Biomedical, Inc.1$18
Cashflow Solutions, LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,576 in reported general payments places this provider in the 75th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$2,948
Medicare patients
29
Services billed
36

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin29$14,810
SantylCollagenase Clostridium Hist.13$6,335
Cefepime Hcl27$4,152
CeftriaxoneCeftriaxone Sodium17$1,939
Linezolid14$376
Triamcinolone Acetonide20$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$704$6,33513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,031 medical providers in Florida.

Other medical in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →